Endocrine Abstracts

Introduction: in X-linked hypophosfatemic rickets (XLH) mutations of PHEX lead to elevated FGF-23 levels. Phosphate salts and calcitriol represented the only treatment option. Tertiary hyperparathyroidism (THPT) is a complication of XLH worsening the clinical features and constituting a contraindication to conventional treatment. Burosumab, a monoclonal antibody anti-FGF23, was recently approved in XLH. No data about Burosumab treatment in patients with XLH and THPT are availa...